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Meshal Almutairi a, Aziz Alanazi aa Prince Sultan Cardiac Center, The Military Hospital, Riyadh; b King Abdulaziz Cardiac Center, University of KSBA for Health
Sciences, Riyadh
a,b Saudi ArabiaBackground: Femoral arterial sheath thrombosis and distal embolization are well-recognized complications of
cardiac catheterization but the occlusion is extremely rare. Heparinized saline flushes are used during diagnostic
coronary angiography to prevent thrombus formation within the sheath lumen. However, the use of prophylactic
intravenous heparin following the femoral arterial sheath insertion is controversial. The aim of this study is to evaluate
the effectiveness of 2000 units of intravenous heparin bolus in comparison to a saline placebo on the thrombus
formation within the arterial sheath during the diagnostic coronary angiography.
Methods: Eligible patients were randomized to receive either a study drug or placebo at the time of femoral sheath
insertion. The sheath was aspirated and flushed for any presence of thrombus after each catheter exchange and at the
end of the procedure. Five milliliters of blood were extracted and visualized on clean gauze followed by a saline
flush. The primary end-point was the effectiveness of the study drug on reducing the incidence of sheath-thrombus
formation.
Results: Three hundred and twenty patients were randomized into two arms. Three hundred and four patients
were analyzed: 147 patients in heparin arm and 157 patients in placebo arm after exclusion of 13 patients in heparin
arm and three in placebo arm because of incomplete reports. The baseline characteristics were similar and sheath-
thrombi formation was observed in 20% of the total cohort.
Of the heparin arm, 12% (19 patients) developed sheath-thrombus formation, whereas 26% (42 patients) in the
placebo arm, p-value = 0.002. An adjusted logistic regression model showed that the only predictor for the sheath-
thrombus formation was the study drug (i.e. heparin). The odds ratio of developing a thrombus in the control
arm was 2.5 (95% CI: 1.4–4.5, p = 0.003). There were no bleeding events observed.
Conclusion: The risk of thrombus formation is significant and intravenous heparin significantly reduced throm-
bus formation during diagnostic coronary angiography, with no excess bleeding events.
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Percutaneous cardiac catheterizations are car-ried out with various types of plastic cathe-
ters with variable thrombogenicity and a variety
of local vascular complications. Catheter manipu-
lations and exchanges directly through the femo-
ral artery may cause repetitive trauma at the
insertion site. Thrombosis at the puncture site
has been reported in 44–54% of percutaneous car-
diac catheterizations [5,15]. However, the clinical
events of thrombotic vascular occlusion are less
common: reports showed that clinical arterial
thrombosis was diagnosed in 0.5–1% of cases
[6,12]. Jacobsson and Schlossman reported femo-
ral arterial thrombotic events in 1.4% of cases,
while Siegelman et al. reported that the surgical
thrombectomy was required in 2.3% of femoral
angiograms made prior to withdrawal of the arte-
rial sheath [9,14].
A heparinized saline flush is used routinely to
prevent thrombus formation within the femoral
sheath lumen during coronary angiography. Sys-
temic heparinization during the catheterization
procedure had been advocated to decrease the
risk of thrombus formation [11]. The available data
are old and no recent trial to assess this issue in
the current advanced technology.
This study was conducted to evaluate the effec-
tiveness of heparin bolus versus saline placebo on
thrombus formation within arterial sheaths dur-
ing the diagnostic coronary angiography.Materials and methods
A single-center, double-blind, randomized con-
trolled trial, evaluating the effectiveness of intra-
venous heparin bolus in the prevention of
femoral arterial sheath-thrombus formation in pa-
tients undergoing diagnostic coronary angiogra-
phy. This included all adult patients undergoing
diagnostic cardiac catheterization, as well as pa-
tients with abnormal coagulation profiles, abnor-
mal platelet counts and those receiving
anticoagulation, or glycoprotein IIb/IIIa antago-
nists were excluded. Patients were recruited from
day-cases and inpatient wards of the Prince Sul-
tan Cardiac Center, Riyadh, Saudi Arabia.
All patients gave informed consent, and the
study protocol was approved by the Institutional
Ethics Committee.
After insertion of the femoral arterial sheath,
each group was allocated to a concealed 2 ml solu-
tion containing either 2000 units of heparin or a
saline placebo which were blinded to both patient
and the operator. Arterial access was obtained viafemoral approach and Super Arrow-flex 6F radi-
opaque polyurethane Sheaths were used. The
type of sheaths and catheters used and the dura-
tion of the procedure were recorded. The femoral
sheath was aspirated and flushed for any presence
of thrombi after each catheter exchange and at the
end of the procedure. A two-step aspiration was
performed where 5 ml of blood were extracted in
one syringe then another saline-filled syringe
was used for flushing. Clean, white gauze was
used to determine any presence of thrombi and,
if thrombi were noticed, further aspiration was
performed followed by a saline flush. Any throm-
bus of any size, as seen by the naked eye, was con-
sidered positive. The patients were evaluated and
assessed clinically during their hospital stay for
any presence of leg ischemia, femoral and pedal
pulses, local hematoma or bleeding.Randomization
Patients were randomized-based on catheteriza-
tion laboratory flow, where the first laboratory was
assigned to treatment number one and the second
laboratory was assigned to treatment number two
on alternate days, with sealed and labeled syrin-
ges that contained the treatment allocation, which
came from pharmacy on a daily basis and were
handed to an independent laboratory staff nurse
assigned to maintain the concealment to patients
and healthcare providers.Outcomes
The primary end-point was the incidence of
arterial sheath thrombi, defined as any visible
thrombus during sheath blood aspiration at any
stage of the procedure.
Patients were monitored for embolic and bleed-
ing events until hospital discharge. Embolic
events were defined as the appearance of symp-
toms and signs of acute limb ischemia (e.g. acute
leg pain and loss of pedal pulses that result in
interventional or surgical exploration). Bleeding
events were defined as local femoral access bleed-
ing or clinically detectable hematoma that leads to
a drop in hemoglobin of more than 1 g/dl or blood
transfusion.
The diagnosis of embolization or hematoma was
made clinically (loss of arterial pulse or evidence
of leg ischemia) and confirmed by Doppler studies
when appropriate.
Outcomes were assessed by the patients’ treat-
ing physicians who were aware of trial assignment
but still blinded for drug assignment.
Figure 1. Incidence of thrombus formation.
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A statistical software package (SAS, Version 9.2,
SAS Institute, and Cary, NC) was used for all sta-
tistical analyses. Categorical data were summa-
rized as frequencies and percentages, and
continuous variables were summarized as means,
medians and standard deviations (SDs). Categori-
cal variables were compared with chi-square test
and continuous variables were compared using
Student’s t-test.
Multivariable logistic regression modeling was
used to identify possible independent predictors
of sheath thrombosis. All variable analysis, as well
as stepwise, forward and backward modeling
techniques, was used. Model calibrations and fit
were assessed with Hosmer–Lemeshow good-
ness-of-fit statistics. A p-value of less than 0.05
was considered significant.Results
Three hundred and twenty patients were ran-
domized into two arms. Three hundred and fourTable 1. Baseline characteristics.
Variable Placebo group (N = 157), N
Age (mean ± SD) 58.2 (±10.6)
Male gender 107 (68)
HTN 106 (71)
DM 90 (61)
Smoking 27 (20)
CAD 98 (70)
Prior MI 37 (29)
CHF 10 (7)
Aspirin 146 (97)
Clopidogrel 135 (92)
Duration of procedure (mean ± SD) 14.4 (±5.9)
Contrast amount (mean ± SD) 42.2 (±19.4)patients were analyzed: 147 patients in heparin
arm and 157 patients in placebo arm after exclu-
sion of 13 patients in heparin arm and three in pla-
cebo arm because of incomplete reports. The
baseline characteristics of the study patients are
presented in Table 1. Hypertension was observed
more in the placebo group than in the treatment
group (71% versus 59%, respectively; p -va-
lue = 0.04). Other variables were not significantly
different between the two groups.
There was no significant influence of procedure
duration and type of contrast used between the
two groups.Efficacy and safety of intravenous heparin
bolus
There were neither bleeding nor clinically
detectable hematomas observed in both groups.
There were no clinical limb ischemia or femoral
embolization observed in this study.
Of the patients who received heparin (19/147),
12% developed femoral sheath thrombi, com-umber (%) Heparin group (N=147), Number (%) p-Value
60.2 (±11.7) 0.14
111 (75) 0.25
79 (59) 0.04
70 (55) 0.3
36 (31) 0.03
77 (62) 0.2
47 (40) 0.09
9 (7) 0.9
138 (98) 0.7
125 (90) 0.6
14.5 (±6.4) 0.8
41.5 (±21.8) 0.76
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(Fig. 1). Among those who were allocated to the
heparin arm, significantly less patients in this
group than in the placebo arm had a femoral
thrombi during diagnostic coronary angiography.
However, there were no clinically significant
ischemic or bleeding events in both groups. The
femoral sheath thrombi were found in 20% (61/
304) of cases, the majority occurring in the placebo
arm 69% (42/61), while 31% (19/61) was found in
the heparin arm. This result was independent of
other factors such as anti-platelet therapy with
aspirin and clopidogrel or the presence of heart
failure. The odds ratio of developing a thrombus
when heparin is not used was 2.5 (95% CI: 1.4–
4.5, p = 0.003); therefore, heparin administration
reduced the incidence of sheath thrombi by 50%
with a 14% absolute risk reduction.Discussion
Percutaneous arterial catheterization using the
Seldinger technique for various vascular catheter-
ization procedures is the standard method of vas-
cular puncture. Our study has shown a 20%
incidence of visible thrombus formation, which
is much lower than what had been reported in
the past (44–54%) [5,14]. The mechanisms of
thrombus formation could be related to local arte-
rial trauma or to the thrombogenic sheath as a for-
eign body inside the artery enhancing the
thrombus deposition. The thrombus formation
was observed as early as 15 min after the introduc-
tion of the catheter [5]. The clinical events of
thrombotic vascular occlusion are less common
and were found in 0.5–1.4% of cases [6,9,12].
Post-cardiac catheterization femoral arterial
thrombosis requiring surgical thrombectomy was
reported in 0.2–2.5% [1–4,8,14]. In our data we ob-
served femoral sheath thrombi in 20% of cases.
This risk was reduced to half by the administra-
tion of intravenous heparin bolus at the time of
the initial vascular access without an increase in
the bleeding risk. Frequent routine aspirations
and heparinized saline flushes are recommended
to maintain sheath patency and prevent any risk
of femoral embolization [15]. Single-dose hepari-
nization is an effective method of reducing the
sheath-thrombus formation during cardiac cathe-
terization. Two thousand units of heparin are safe,
easily administered, and has a rapid onset [8,11].
We would encourage the routine use of systemic
heparinization, when not specifically contraindi-
cated, regardless of the approach. Our report
stresses the necessity of systemic heparinizationto prevent arterial sheath-thrombus formation
during diagnostic cardiac catheterization. Other
trials have shown similar results with an initial bo-
lus of 2000–5000 units of heparin followed by cath-
eter flushing with heparinized saline flushes
produced decreased thrombosis risk for the dura-
tion of the study, and was considered the method
of choice [7,10,13]. There was no increased fre-
quency of hemorrhagic complications.Study limitations
Despite being a randomized study, it represents
a small sample size and single-center trial. An-
other potential limitation is common use of antico-
agulation with enoxaparin and heparin as well as
glycoprotein inhibitors in acute coronary syn-
drome patients excluding them from the study.
On the other hand, the study was inadequately
powered to assess for differences in hemorrhagic
complications.Conclusion
The risk of thrombus formation is significant
and use of low dose heparin is a direct, effective
and safe method of preventing arterial sheath for-
mation during diagnostic percutaneous coronary
arteriography with no increase in hemorrhagic
complications at this dose.Future research
Further studies are required to confirm the
prevalence of thrombus formation and its clinical
impact in a large data.Disclosures
All authors have no conflict of interests to
disclose.
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